Following the strategy of the Group, Tecnimede España emerged in 1999 as a result of a growing bet on the internationalization and in the recognition of the high potential of the Spanish medicinal product market.
Being dedicated to the development and marketing of generic medicinal products, Tecnimede España currently distributes, under the brand Tecnigen, over than 55 molecules in different therapeutic areas, of which are highlighted three absolute novelties on the Spanish market: ramipril/hidroclorotiazida TecniGen EFG, Sildenafilo Tecnigen EGF and Acarbosa TecniGen.
In the next years, based fundamentally on the molecules developed by the Tecnimede Group, the number of marketed products is estimated to double.
Tecnimede España intends to establish on the Spanish market as an innovative company and as a quality and trust partner. Its strength and added value are based essentially on the human capital, in the team with high technical ability, well prepared and most of all, motivated to properly meet the needs of pharmacists, physicians, patients and of the society in general.